![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » House Democrats Unveil Bill to Cut Exclusivity for Innovator Biologics
House Democrats Unveil Bill to Cut Exclusivity for Innovator Biologics
![](https://www.fdanews.com/ext/resources/test/Device_Images/dna-strand-blue.jpg?t=1433878526&width=430)
June 29, 2016
House Democrats took aim at the biopharmaceutical industry last week, introducing a bill that would cut patent exclusivity for innovators nearly in half.
The bill — sponsored by Rep. Janice Schakowsky (D-Ill.) — would amend the Public Health Service Act to shorten exclusivity for brand name biologics from 12 years to 7 years.
BIO slammed the bill in a statement, describing it as a means to “undermining investment in the next biomedical breakthroughs for patients.”
Upcoming Events
-
21Oct